Blood Res.  2021 Dec;56(4):349-353. 10.5045/br.2021.2021197.

Therapy-related myeloid neoplasms after transcatheter arterial chemoembolization for hepatocellular carcinoma

• Yi JH
• Jang JH
• Jung CW

• KMID: 2524100
• DOI: http://doi.org/10.5045/br.2021.2021197

Reference

1. Swerdlow SH, Campo E, Harris NL, et al. 2017. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. IARC Press;Lyon, France:

2. Kayser S, Döhner K, Krauter J, et al. 2011; The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 117:2137–45. DOI: 10.1182/blood-2010-08-301713. PMID: 21127174.

3. Cowell IG, Austin CA. 2012; Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents. Int J Environ Res Public Health. 9:2075–91. DOI: 10.3390/ijerph9062075. PMID: 22829791. PMCID: PMC3397365.

4. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. 2015; Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National Population-Based Cohort Study. J Clin Oncol. 33:3641–9. DOI: 10.1200/JCO.2014.60.0890. PMID: 26304885.

5. Hulegårdh E, Nilsson C, Lazarevic V, et al. 2015; Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 90:208–14. DOI: 10.1002/ajh.23908. PMID: 25421221.

6. Sanz MA, Lo Coco F, Martín G, et al. 2000; Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 96:1247–53. PMID: 10942364.

7. Döhner H, Estey E, Grimwade D, et al. 2017; Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–47. DOI: 10.1182/blood-2016-08-733196. PMID: 27895058. PMCID: PMC5291965.

8. Greenberg PL, Tuechler H, Schanz J, et al. 2012; Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 120:2454–65. DOI: 10.1182/blood-2012-03-420489. PMID: 22740453. PMCID: PMC4425443.

9. Cheson BD, Bennett JM, Kopecky KJ, et al. 2003; Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 21:4642–9. DOI: 10.1200/JCO.2003.04.036. PMID: 14673054.

10. Cheson BD, Greenberg PL, Bennett JM, et al. 2006; Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 108:419–25. DOI: 10.1182/blood-2005-10-4149. PMID: 16609072.

11. McNerney ME, Godley LA, Le Beau MM. 2017; Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 17:513–27. DOI: 10.1038/nrc.2017.60. PMID: 28835720. PMCID: PMC5946699.

12. Suzukawa M, Nakazora T, Kawasaki Y, Tominaga T, Shinohara K. 2010; Massive ascites associated with all-trans retinoic acid treatment in therapy-related acute promyelocytic leukemia. Intern Med. 49:457–60. DOI: 10.2169/internalmedicine.49.2733. PMID: 20190483.

13. Park SH, Chi HS, Cho YU, Jang S, Park CJ. 2013; Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia. Blood Res. 48:185–92. DOI: 10.5045/br.2013.48.3.185. PMID: 24086938. PMCID: PMC3786278.

14. Alexander SI, Smith N, Hu M, et al. 2008; Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med. 358:369–74. DOI: 10.1056/NEJMoa0707255. PMID: 18216357.

15. Litzow MR, Tarima S, Pérez WS, et al. 2010; Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 115:1850–7. DOI: 10.1182/blood-2009-10-249128. PMID: 20032503. PMCID: PMC2832815.